The Discussions are Constructive
Consultations on PFAS restriction in the EU are making progress.
Interview
14.05.2025 • News • Technology
Smart Tools for a Plastic-Free Future
Cutting Time and Cost of Developing Sustainable Products with AI-Powered Solutions
14.05.2025 • Topics • Innovation
Motivation, Innovation, and the Power of Collaboration
Leading the Way in Pharmaceutical Manufacturing by Fostering an Agile Mindset and an Inclusive Culture.
“Access to Talent is a Crucial Factor”
In an interview with CHEManager, Edgardo Hernandez, President of Lilly Manufacturing, explains the strategy behind the ambitious investment project.
Specialty Chemicals in a Shifting World
Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.
Fostering Innovation and Collaboration
Valerie Diele-Braun, CEO of IMCD, shares her vision for sustainability, global expansions, and strategic direction in an exclusive CHEManager International interview.
Supply Chain and Logistics Trends in the Chemical Industry
This interview covers key results of the study ‘Success Factor Supply Chain Management and Logistics in the Chemical Industry 2024’ by Solventure, Aimms and Miebach.
19.03.2025 • News • Innovation
Data-Driven Enzyme Immobilization
Inseit, based in Bern, develops biocatalysts for industrial setups using enzyme immobilization and biocomputation. Addressing biotech and sustainability challenges, Inseit was selected for Venture Leaders Biotech and won two Nucleate accelerator prizes.
19.03.2025 • News • Innovation
High-Performance Adsorbents: The Future of Clean Industry
Porelio's FOMS adsorbents target PFAS, metals, and genotoxins, outperforming commercial solutions with unmatched selectivity, innovation, and sustainability.
17.02.2025 • Topics • Digitalization
Innovation at the Intersection of AI
John Banovetz, Chief Technology Officer at 3M, on the role of digital transformation in realizing the company's goals.
Next Level Chemical Distribution
Dorothee Arns, Director General of FECC, discusses current challenges, market trends and her vision for the chemical distribution industry in Europe.
Expert Statement: Frank Ferrante, Cambrex
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
11.09.2024 • Topics • Bioprocessing
Insights into Biologics and Pharmaceutical Manufacturing
Bill Humphries, CEO of Alcami, shares his vision for the future, discussing dynamic market trends and the company’s commitment to innovation. Under his leadership, Alcami is poised to redefine the pharmaceutical and biotechnology landscape, focusing on cutting-edge solutions and navigating global complexities. This conversation highlights Alcami’s strategic direction, accomplishments, and upcoming challenges.
Uncovering Potential
Interview with Olivier Lambrechts, executive leadership team member and president NCE at Arxada.
Pharma’s Digital Transformation
Industry experts Michelangelo Canzoneri, Josef Trapl, Wolfgang Winter, Christian Woelbeling, and Thomas Zimmer – all members of ISPE’s Pharma 4.0 guide core team – explain the transformational challenges and critical success factors of the digital Pharma 4.0 journey.
Preparing for the future — TCO-optimized investments
Interview with Fernando Cruzado, Vice President and Industry Lead Chemistry, and Holger Peterkord, Senior Principal and Capex Practice Lead, Efeso Group
Expert Statement: Martin Meeson, Axplora
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Torsten Wöhr, Bachem
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Neil Jones, Aenova
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Victor Swint, Formulated Solutions
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Akhil Ravi, Aurigene Pharmaceutical Services
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Yu Lu, WuXi STA
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Jordi Robinson, Navin Molecular
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Greg Behar, Recipharm
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Alex Del Priore, Syngene
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Chad Telgenhof, Sterling Pharma Solutions
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Thomas Otto and Peter Soelkner, Vetter
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Rohtash Kumar, Veranova
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Tom Wilson, Pfizer
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Davuluri Saharsh Rao, Neuland Labs
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Federico Pollano, Rentschler
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Prasad Raje, LGM Pharma
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Christoph Schaffrath, Lanxess
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Gordon Bates, Lonza
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Kenneth N. Drew, Flamma
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
